The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Open accessAbstract
BACKGROUND: Closed-loop systems that automate insulin delivery may improve glycemic outcomes in patients with type 1 diabetes. METHODS: In this 6-month randomized, multicenter trial, patients with type 1 diabetes were assigned in a 2:1 ratio to receive treatment with a closed-loop system (closed-loop group) or a sensor-augmented pump (control group). The primary outcome was the percentage of time that the blood glucose level was within the target range of 70 to 180 mg per deciliter (3.9 to 10.0 mmol per liter), as measured by continuous glucose monitoring. RESULTS: A total of 168 patients underwent randomization; 112 were assigned to the closed-loop group, and 56 were assigned to the control group. The age range of the patients was 14 to 71 years, and the glycated hemoglobin level ranged from 5.4 to 10.6%. All 168 patients completed the trial. The mean (±SD) percentage of time that the glucose level was within the target range increased in the closed-loop group from 61±17% at baseline to 71±12% during the 6 months and remained unchanged at 59±14% in the control group (mean adjusted difference, 11 percentage points; 95% confidence interval [CI], 9 to 14; P<0.001). The results with regard to the main secondary outcomes (percentage of time that the glucose level was >180 mg per deciliter, mean glucose level, glycated hemoglobin level, and percentage of time that the glucose level was <70 mg per deciliter or <54 mg per deciliter [3.0 mmol per liter]) all met the prespecified hierarchical criterion for significance, favoring the closed-loop system. The mean difference (closed loop minus control) in the percentage of time that the blood glucose level was lower than 70 mg per deciliter was -0.88 percentage points (95% CI, -1.19 to -0.57; P<0.001). The mean adjusted difference in glycated hemoglobin level after 6 months was -0.33 percentage points (95% CI, -0.53 to -0.13; P = 0.001). In the closed-loop group, the median percentage of time that the system was in closed-loop mode was 90% over 6 months. No serious hypoglycemic events occurred in either group; one episode of diabetic ketoacidosis occurred in the closed-loop group. CONCLUSIONS: In this 6-month trial involving patients with type 1 diabetes, the use of a closed-loop system was associated with a greater percentage of time spent in a target glycemic range than the use of a sensor-augmented insulin pump. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases; iDCL ClinicalTrials.gov number, NCT03563313.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The largest trial with this class in T1D was with liraglutide, which showed a reduction of A1C of 0.4% with the highest 1.8 mg dose in addition to a 5 kg weight loss and insulin dose reductions.1177”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1177]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, the introduction of CGM devices that alarm with low blood glucose concentrations and semiautomated pumps that suspend insulin infusion as glucose concentrations decrease have facilitated achieving target HbA 1c levels with less risk for hypoglycemia (332).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [332]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hybrid closedloop systems are the most effective means of maintaining glucose in the normal range in people with type 1 diabetes (90,91).”
From The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2021) · cites this paper as [91]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The use of insulin analog regimens are associated with less hypoglycemia, while hybrid closed-loop systems result in both improvement in TIR and reduction in TBR (91).”
From The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2021) · cites this paper as [91]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These prestigious publications reported pivotal trials of the commercial descendant of DiAs-a new AID system (Control-IQ by Tandem Diabetes Care)-in different age groups: 14 years old and older, 132 6 to 13 years old, 133 and 2 to 6 years old.134”
From Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility (2023) · cites this paper as [132]
The cited source says what the claim attributes to it.
In the citing paper
“This large-scale study and its continuation with young children ages 2 to 6 years old completed several clinical protocols, three of which were published in the New England Journal of Medicine.[132][133][134]”
From Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility (2023) · cites this paper as [132]
The cited source says what the claim attributes to it.
In the citing paper
“In particular, glucose time in range (70 -180 mg/dl [3.9 -10.0 mmol/l]) and time in hypoglycemia ( < 70 mg/dl [3.9 mmol/l] and < 54 mg/dl [3.0 mmol/l]) have been used as outcomes for clinical trials 259,260 and have been endorsed as appropriate metrics for clinical care. 229”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [260]
The cited source says what the claim attributes to it.
In the citing paper
“Evidence suggests that an AID hybrid closed-loop system is superior to AID sensor-augmented pump therapy for increased percentage of time in range and reduction of hypoglycemia (34,35).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [34]
The cited source says what the claim attributes to it.
In the citing paper
“HbA 1c , TIR, and TBR are improved further when physiological MDI or pump regimens are augmented with CGM usage (89), with the greatest benefits seen with algorithm-driven automated basal (and in some systems correction) insulin delivery, which is commonly called hybrid closed-loop therapy (90,91).”
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although this agent was more effective with those participants still producing endogenous insulin, the added hypoglycemia and ketosis noted has resulted in no attempt for FDA approval in T1D.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1177]
Experimental — accuracy not yet measuredIn the citing paper
“all AID system pivotal trials that examined individuals 2 years old or older, including older adults, have consistently demonstrated superiority to either standard insulin delivery (or manual mode for the single-arm studies) or SAP and/or usual care (for the randomized trials)”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [208]
In the citing paper
“with consistent improvement in A1C, increase in TIR, especially overnight, as well as reduction of time spent in hypoglycemia (207-219).”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [208]
In the citing paper
“with consistent improvement in A1C, increase in TIR, especially overnight, as well as reduction of time spent in hypoglycemia (207-219).”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [208]
In the citing paper
“with consistent improvement in A1C, increase in TIR, especially overnight, as well as reduction of time spent in hypoglycemia (207-219).”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [208]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018
Foster, N. C., Beck, R. W., Miller, K. M., Clements, M. A., Rickels, M. R., DiMeglio, L. A., Maahs, D. M., Tamborlane, W. V., Bergenstal, R., Smith, E., et al. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0384 · Cited by 1,907
Self-citation6. Glycemic Targets: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s006 · Cited by 655
Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644
Self-citationWeisman, A., Bai, J.-W., Cardinez, M., Kramer, C. K., & Perkins, B. A. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30167-5 · Cited by 463
Tauschmann, M., Thabit, H., Bally, L., Allen, J. M., Hartnell, S., Wilinska, M. E., Ruan, Y., Sibayan, J., Kollman, C., Cheng, P., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31947-0 · Cited by 440
Self-citationBekiari, E., Kitsios, K., Thabit, H., Tauschmann, M., Athanasiadou, E., Karagiannis, T., Haidich, A.-B., Hovorka, R., & Tsapas, A. (2018) · BMJ · doi:10.1136/bmj.k1310 · Cited by 437
Kleinman, L. C., & Norton, E. C. (2008) · Health Services Research · doi:10.1111/j.1475-6773.2008.00900.x · Cited by 287
Forlenza, G. P., Li, Z., Buckingham, B. A., Pinsker, J. E., Cengiz, E., Wadwa, R. P., Ekhlaspour, L., Church, M. M., Weinzimer, S. A., Jost, E., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0771 · Cited by 246
Self-citationBenhamou, P.-Y., Franc, S., Reznik, Y., Thivolet, C., Schaepelynck, P., Renard, E., Guerci, B., Chaillous, L., Lukas-Croisier, C., Jeandidier, N., et al. (2019) · The Lancet Digital Health · doi:10.1016/s2589-7500(19)30003-2 · Cited by 217
Cited by
Sorted by citations
Items 701–800 of 999
Technological Innovations in Type 1 Diabetes Mellitus Management: A Narrative Review
Gunatilake, S. S. C. (2024) · Sri Lanka Journal of Diabetes Endocrinology and Metabolism · doi:10.4038/sjdem.v15i1.7534 · Cited by 3
Advanced biomaterials for diabetes healthcare and complication therapy: A review
Wang, G., Liao, W., Han, F., Shi, Y., & Hu, Z. (2024) · APL Materials · doi:10.1063/5.0237243 · Cited by 3
Cai, Y., Ma, L., Zhang, L., Qiongli, N., & Su, H. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0591 · Cited by 4
Wilkinson, T., Donnelly, S., Lever, C. S., Williman, J. A., Meier, R. A., Boucsein, A., Jones, S., Ballagh, D., van Rensburg, R., Sampson, R., et al. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251349528 · Cited by 3
Glycemic variability and iatrogenic hypoglycemia: how to resolve
Monnier, L., Colette, C., Renard, É., Benhamou, P., Aouinti, S., Molinari, N., & Owens, D. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112360 · Cited by 3
Diabetes Update 2020: das Wichtigste für die ärztliche Praxis
Scherbaum, W. A. (2020) · Der Diabetologe · doi:10.1007/s11428-020-00642-7 · Cited by 3
Automatic Regulation of Basal Insulin Infusion in a Personalized Insulin Therapy System
Litinskaia, E. L., Витольдович, П. К., & Polyakova, E. A. (2021) · Biomedical Engineering · doi:10.1007/s10527-021-10041-x · Cited by 3
Steenkamp, D., Piarulli, A., Middelbeek, R. J. W., & Wolpert, H. A. (2022) · Diabetic Medicine · doi:10.1111/dme.14975 · Cited by 3
Glucose Control in the Intensive Care Unit
Gunst, J., & den Berghe, G. V. (2020) · Springer eBooks · doi:10.1007/978-3-030-53370-0_42 · Cited by 3
The Present and Future of Continuous Glucose Monitoring
Jin, S. (2020) · Journal of Korean Diabetes · doi:10.4093/jkd.2020.21.4.179 · Cited by 3
New technical approach to the diabetes therapy
Dovč, K., & Battelino, T. (2020) · Minerva Pediatrics · doi:10.23736/s0026-4946.20.05865-x · Cited by 3
Type 1 Diabetes in Children and Adolescents
Hu, P., Name, M. A. V., Stephenson, K., Sikes, K. A., & Tamborlane, W. V. (2024) · Springer eBooks · doi:10.1007/978-3-031-66296-6_30 · Cited by 3
On the Path toward Expanding Treatment Options for Diabetes
Brown, S. A. (2022) · New England Journal of Medicine · doi:10.1056/nejme2209840 · Cited by 4
Self-citationInpatient Use of Automated Insulin Delivery Systems
Chadalawada, L., Parab, R., Feeley, J. M., Hughes, M. S., Pasquel, F. J., & Davis, G. M. (2026) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251412442 · Cited by 3
Johnson, J., Franklin, V. L., Shepherd, A. J., Chau, G., Keen, K., Lennon, S., Leveridge, M., Maclean, K., Nicol, J., Phillipson, V., et al. (2025) · Pediatric Diabetes · doi:10.1155/pedi/5545726 · Cited by 2
Franzone, D., Spacco, G., Piano, A., Siri, G., Tantari, G., d’Annunzio, G., Calevo, M. G., Maghnie, M., Minuto, N., & Bassi, M. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1590964 · Cited by 3
Diabetes Without Math as Automation Advances: A Shifting Clinical Paradigm
Mora, P. A., Cook, K. P., & MacLeod, J. (2025) · Diabetes Technology and Obesity Medicine · doi:10.1089/dtom.2025.0033 · Cited by 2
Royston, C., Ware, J., Allen, J. M., Wilinska, M. E., Hartnell, S., Thankamony, A., Randell, T. L., Ghatak, A., Besser, R. E. J., Elleri, D., et al. (2025) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251369882 · Cited by 2
Sawyer, A., Forlenza, G. P., & Wadwa, R. P. (2025) · Expert Review of Medical Devices · doi:10.1080/17434440.2025.2585061 · Cited by 2
Self-citationReal-World HbA1c Following Initiation of the Omnipod 5 Automated Insulin Delivery System
Levy, C. J., Carlow, D., Swift, D., Rittgers-Simonds, R., Gronroos, N. N., Walker, V., Buysman, E. K., & Forlenza, G. P. (2025) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251395014 · Cited by 2
Self-citationChahal, T., Alexandre‐Heymann, L., Yardley, J. E., Grou, C., Guédet, C. G., Messier, V., Boudreau, V., Courchesne, A., Brazeau, A., RABASA-LHORET, R. P. R., et al. (2025) · Diabetic Medicine · doi:10.1111/dme.70192 · Cited by 2
Kim, J. Y., Kim, N. H., Kwak, S. H., Jung, C. H., Kang, E. S., Moon, J. S., Moon, S. J., Kwon, S. Y., Yoo, J. H., Kim, Y., et al. (2025) · Endocrinology and Metabolism · doi:10.3803/enm.2025.2579 · Cited by 2
Revolutionizing Diabetes Care: From Tech to Therapeutics
Aktürk, H. K., WATERMAN, L. A., & Cobry, E. C. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s580423 · Cited by 2
Cherubini, V., Franceschi, R., Faragalli, A., Bassi, M., Bonfanti, R., Bracciolini, G., Felappi, B., Foglino, R., Iafusco, D., Lasagni, A., et al. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.103829 · Cited by 2
Chronic Disease Monitoring Using Advanced Compliant Materials for Bioelectronics
Kim, H., Bartlett, M., Wang, L., Bates, K., He, M., Kim, M., Majidi, C., & Cohen‐Karni, T. (2026) · Advanced Electronic Materials · doi:10.1002/aelm.202500885 · Cited by 2
Julla, J., Amouyal, C., Lablanche, S., Sola‐Gazagnes, A., Joubert, M., Hadjadj, S., Signor, C. B., Bismuth, É., Chartier, Y., Garrec, N., et al. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261465478 · Cited by 2
Ye, M., & Arnold, M. A. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.1c00300 · Cited by 2
Improving HbA1c levels with advanced hybrid closed-loop therapy
Jacobs, P. G. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00245-5 · Cited by 2
Gouet, D., Ducluzeau, P., Andriantaolo, H., Cordroc'h, C., Duengler, F., Gaulier, S., Godeau, T., Olivier, C., & Allix‐Béguec, C. (2022) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2022.100110 · Cited by 2
Health-Care Disparities in the Use of Diabetes Technologies in the UK
Barnard-Kelly, K. D., & Parkin, C. G. (2022) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_1_23 · Cited by 2
Current Trends and Strategies for Exercise in Diabetes
Patton, S. R., & Riddell, M. C. (2023) · Diabetes Spectrum · doi:10.2337/dsi22-0019 · Cited by 4
Pasqua, M., Odabassian, M., Tsoukas, M. A., & Haidar, A. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231176302 · Cited by 2
Acceptance of encapsulated porcine islet xenotransplantation by patients and doctors in the US
Matsumoto, S., & Yamamoto, N. (2023) · Medicine Advances · doi:10.1002/med4.29 · Cited by 2
Insulin’s Legacy: A Century of Breakthroughs and Innovation
Hadid, S. A., Zhang, E., Frishman, W. H., & Brutsaert, E. F. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000680 · Cited by 2
Forlenza, G. P., Tabatabai, I., & Lewis, D. M. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0073 · Cited by 2
Self-citationFerguson, A. M., & Lin, A. C. (2024) · Annals of Biomedical Engineering · doi:10.1007/s10439-024-03529-6 · Cited by 2
Boughton, C. K., Allen, J. M., Ware, J., Wilinska, M. E., Hartnell, S., Thankamony, A., Randell, T. L., Ghatak, A., Besser, R. E. J., Elleri, D., et al. (2024) · Efficacy and Mechanism Evaluation · doi:10.3310/ktfr5698 · Cited by 2
Gawrecki, A., Chrzanowski, J., Michalak, A., Fendler, W. M., Cohen, O., & Szadkowska, A. (2024) · Hormone Research in Paediatrics · doi:10.1159/000542204 · Cited by 2
Diabetes in Children and Adolescents
Šumnı́k, Z., & Průhová, Š. (2024) · Endocrinology · doi:10.1007/978-3-030-23709-7_10 · Cited by 2
Onetto, M. T., Montt‐Blanchard, D., Berget, C., Strodhoff, K., & Grassi, B. A. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70034 · Cited by 2
Kelly, J., Steenkamp, D., Brouillard, E., & Wolpert, H. A. (2025) · Diabetic Medicine · doi:10.1111/dme.70031 · Cited by 2
Navigating Automated Insulin Delivery for Type 1 Diabetes Management During Pregnancy
Scifres, C., Cleary, E. M., Sheerer, M., Bowdler, M., & Shah, V. N. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251334597 · Cited by 2
A Review on the Diabetes Treatment Using Artificial Intelligence and Machine Learning
Waghmare, P., & Verma, P. (2025) · International Conference on Inventive Computation Technologies (ICICT) · doi:10.1109/icict64420.2025.11004911 · Cited by 2
Early Stages of Automated Insulin Delivery
Zisser, H., Hovorka, R., Basu, A., Battelino, T., Boughton, C. K., Breton, M. D., Buckingham, B. A., Brown, S. A., Cherñavvsky, D. R., Dassau, E., et al. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2025.18802.hz · Cited by 3
Self-citationRaile, K., Boß, K., Braune, K., & Heinrich-Rohr, M. (2020) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-020-03162-3 · Cited by 2
Diabetes Technology and Therapy in the Pediatric Age Group
Maahs, D. M., Addala, A., & Shalitin, S. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.2507 · Cited by 2
Adaptive and Individualized Artificial Pancreas for Precision Management of Type 1 Diabetes
Toffanin, C., Cobelli, C., & Magni, L. (2022) · Springer eBooks · doi:10.1007/978-3-030-98927-9_15 · Cited by 3
A novel cellular engineering approach to diabetes mellitus
Weir, G. C. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0389-x · Cited by 2
Baura, G. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-811984-6.00020-9 · Cited by 2
Insulin Delivery: An Evolution in the Technology
Kesavadev, J., Krishnan, G., & Benny, N. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_69 · Cited by 2
Cropley, D. H., & Cropley, A. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91841-1.00002-6 · Cited by 2
Reflections on Diabetes Care at the End of the Second Decade of the 21st Century
Garg, S. K. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0014 · Cited by 2
Immune Digital Twin Blueprint: A Comprehensive Mechanistic Model of the Human Immune SystemPreprint
Amin, R., Aghamiri, S. S., Puniya, B. L., Mayo, L., Startsev, D., Poore, K., Helikar, R., & Helikar, T. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.11.988238 · Cited by 3
Diabetes and Technology in the Covid-19 Pandemic Crisis
Spanakis, E. K. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820929385 · Cited by 2
Ware, J., Boughton, C. K., Allen, J. M., Wilinska, M. E., Tauschmann, M., Denvir, L. A., Thankamony, A., Campbell, F., Wadwa, R. P., Buckingham, B. A., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3893537 · Cited by 2
Self-citationDiabetes Care for the Aging Population in the Digital Age
Munshi, M. N., & Toschi, E. (2024) · NEJM Evidence · doi:10.1056/evide2400389 · Cited by 2
The Evolution of Do-It-Yourself Brain Hacking: From Fringe to Frontier
Lakhan, S. E. (2025) · Cureus · doi:10.7759/cureus.85330 · Cited by 3
Tung, J. Y., Gower, S., Ooteghem, K. V., Nouredanesh, M., & Gage, W. H. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818914-6.00008-9 · Cited by 2
Schoelwer, M. J., Bisio, A., Breton, M. D., & DeBoer, M. D. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0405 · Cited by 1
Diabetes Technology and Therapy in the Pediatric Age Group
Maahs, D. M., Prahalad, P., Schweiger, D. Š., & Shalitin, S. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.2508 · Cited by 1
Automatic Control in Systems Biology
Balakrishnan, N., & Bagheri, N. (2023) · Springer handbooks · doi:10.1007/978-3-030-96729-1_55 · Cited by 1
2023 Clinical Practice Guidelines for Diabetes: Continuous Glucose Monitoring and Insulin Pumps
Jin, S. (2023) · Journal of Korean Diabetes · doi:10.4093/jkd.2023.24.3.141 · Cited by 1
Ibrahim, M., Beneyto, A., Contreras, I., & Vehı́, J. (2023) · IFAC-PapersOnLine · doi:10.1016/j.ifacol.2023.10.441 · Cited by 1
Model Predictive Control with Dynamic Positive Input Extension for Artificial Pancreas Applications
Novák, K., Siket, M., Kovács, L., Drexler, D. A., Rudas, I. J., & Eigner, G. (2023) · Conference proceedings/Conference proceedings - IEEE International Conference on Systems, Man, and Cybernetics · doi:10.1109/smc53992.2023.10394179 · Cited by 1
An unmet need: Pancreatic beta cell replacement
Mohamed, F., Adams, C., & Mansfield, B. S. (2024) · South African Medical Journal · doi:10.7196/samj.2024.v114i3b.1249 · Cited by 2
Islet transplantation in Korea
Lee, J., & Yoon, K.-H. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14264 · Cited by 3
Aboznadah, W. M., Tsoukas, M. A., Hu, X., & Pasqua, M. (2025) · JCEM Case Reports · doi:10.1210/jcemcr/luaf021 · Cited by 1
Zahradnická, M., Németová, L., Kahle, M., Vávra, D., Bém, R., Girman, P., Haluzı́k, M., & Saudek, F. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0606 · Cited by 1
Jenkins, J. G., Cocks, M. S., Narendran, P., Andrews, R. C., Shields, B. M., Scott, S. N., Lucas, S. J. E., Rendeiro, C., & Hesketh, K. L. (2025) · BMJ Open Sport & Exercise Medicine · doi:10.1136/bmjsem-2025-002594 · Cited by 1
Artificial Pancreas: The First 20 Years
Doyle, F. J., & Kovatchev, B. P. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251330920 · Cited by 1
Self-citationHayek, A. A., Alzahrani, W. M., Saeed, A. H. A., Mashali, M. A., Klonoff, D. C., & Dawish, M. A. A. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03326-0 · Cited by 2
Rateb, R. M., Salah, A., Kertam, A., Ashmawi, Y. A. Y., Mahmoud, N. H., Afifi, E., Bayoumi, A., Allam, S., & Rakab, M. S. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01906-2 · Cited by 1
Gómez‐Perea, A., Jurado, A. L., Gutiérrez, S. G., Guerrero‐del‐Cueto, F., García-Ruiz, A., Torre, C. L.-D. L., Cardona, F., & Gea, I. L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199638 · Cited by 1
Manjelievskaia, J., Shah, V. N., Carlson, A. L., Isaacs, D. M., Wang, S. M., Pinsker, J. E., Messer, L. H., McDermott, K. W., Lavelle, K., Wall, S., et al. (2025) · Diabetic Medicine · doi:10.1111/dme.70147 · Cited by 1
Self-citationLockee, B., Vandervelden, C. A., Tilden, D. R., Panfil, K., Tallon, E. M., DeWit, E., Noland, K., Williams, D. D., Gill, H. S., Patton, S. R., et al. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251367776 · Cited by 2
Faragalli, A., Franceschi, R., Marigliano, M., Cherubini, V., Gesuita, R., & Diabetes Study Group of the Italian Society for Pediatric Endocrinology and Diabetology (2025) · Epidemiology Biostatistics and Public Health · doi:10.54103/2282-0930/29451 · Cited by 1
Pilot Study of Early Adoption of Automated Insulin Delivery in Underresourced Youth
Yen, K., Belapurkar, S., Puckett, C., Chen, N. S., YGLECIAS, L., Bal, K., Hickey, J., CARELLI, L. L., LOUCEL, C. M., Lodish, M. B., et al. (2025) · Journal of Diabetes Research · doi:10.1155/jdr/6886806 · Cited by 2
A hypothesis of Cybernetic Medicine: Redefining health and disease through control theory
Wang, S., & Li, X. (2025) · Medical Hypotheses · doi:10.1016/j.mehy.2025.111823 · Cited by 1
Automated Insulin Delivery Beyond Glycemic Outcomes: Endpoints and Evidence
Jones, H. C., Trawley, S. L., Jenkins, A. J., MacIsaac, R. J., Kong, Y. W., Morrison, D., & O'Neal, D. N. (2025) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251390831 · Cited by 1
Angelino, S., Maiorino, M. I., Petrizzo, M., Martino, N. D., Caruso, P., Carbone, C., Pontillo, A., Maio, A., Longo, M., Scappaticcio, L., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1717249 · Cited by 1
Benhamou, P., Vesin, A., Reynaud, L., & Chatel, B. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251404493 · Cited by 1
Rangel-Osuna, F., Infante-Xibille, C., & Orozco-Núñez, E. (2025) · Revista Panamericana de Salud Pública · doi:10.26633/rpsp.2025.130 · Cited by 1
Griffin, T. P., Hagan, J., Chauhan, R., Crabtree, T. S. J., Ackroyd, D., Elliott, J., Narendran, P., Bawlchhim, Z., Wilmot, E. G., Hadjiconstantinou, M., et al. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113084 · Cited by 1
Cao, C., Xue, P., Yang, X., Huang, F., Xie, Y., & Zhou, Z. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1736477 · Cited by 1
Sidki, A., HIGHTON, P. J., O’Mahoney, L. L., & Wilkinson, T. J. (2026) · Diabetic Medicine · doi:10.1111/dme.70210 · Cited by 1
Sørensen, M. Z., Andersen, T. H., Suvitaival, T., Svensson, J., Nørgaard, K., & Christensen, M. H. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251411925 · Cited by 1
Kirton, L. W., Cook, J., Hamill, R., Kingi, T., Kivi, N., Eathorne, A., Rogan, A., Weatherall, M., & Beasley, R. W. (2026) · Emergency Medicine Journal · doi:10.1136/emermed-2024-214023 · Cited by 1
Perioperative Medication Management for Patients with Diabetes
Duggan, E. W., & Mazer, C. D. (2026) · Medical Clinics of North America · doi:10.1016/j.mcna.2025.11.010 · Cited by 1
Recent Advances in the Management of Type 1 Diabetes in Children
Beck, N. L. (2026) · Advances in Pediatrics · doi:10.1016/j.yapd.2025.12.012 · Cited by 1
Parimi, N., Wu, C., Ziglar, J., Brown, E. A., Sidhaye, A. R., Mathioudakis, N. N., & Wolf, R. M. (2026) · Journal of Diabetes Science and Technology · doi:10.1177/19322968261426387 · Cited by 1
Liu, Y., Wang, Y., Wu, W., Chen, Y., Zeng, T., Li, X., Zheng, C., Li, Y., Wu, X., Yao, H., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70709 · Cited by 1
JENDLE, J. H., Picado, N., Bulhosa, C., Janssen, M., Lepzien, R., Fiorentino, F., Wang, S. M., Patel, B. V., Ekelund, C., & Adolfsson, P. (2026) · Diabetic Medicine · doi:10.1111/dme.70355 · Cited by 1
Wolf, R. M., OSPELT, E. L., VORA, D., Odugbesan, O., Brown, E. A., Wong, J. C., March, C. A., & Mathioudakis, N. N. (2026) · Journal of Diabetes Science and Technology · doi:10.1177/19322968261459450 · Cited by 1
Bioengineering needs systems thinking
(2026) · Nature Reviews Bioengineering · doi:10.1038/s44222-026-00469-9 · Cited by 1
Song, J., Tao, W., Zhou, D., 李轩宾, Peng, S., Li, C., & Yuan, J. (2026) · Medicine · doi:10.1097/md.0000000000049815 · Cited by 1
Ayhan, D. B., & Özdemi̇r, S. (2026) · Journal of Pediatric Nursing · doi:10.1016/j.pedn.2026.08.011 · Cited by 1
Manski-Nankervis, J.-A. E., Cheungpasitporn, W., Garg, A. X., Graham-Brown, M. P. M., Griva, K., Samal, L., Stevens, P. E., Tangri, N., Spall, H. G. C. V., Cheung, M., et al. (2026) · Kidney International · doi:10.1016/j.kint.2026.09.015 · Cited by 1
Gujral, J., Sethuram, S., & Rapaport, R. (2019) · Journal of Diabetes · doi:10.1111/1753-0407.13012 · Cited by 1
Wo steht das künstliche Pankreas in der Diabetestherapie?
Dimou, M., Laimer, M. W., Stettler, C., & Bally, L. (2019) · Der Internist · doi:10.1007/s00108-019-00713-y · Cited by 1
ROLE OF ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT
Mishra, D. K., & Shukla, S. (2020) · International Journal of Engineering Technologies and Management Research · doi:10.29121/ijetmr.v7.i7.2020.728 · Cited by 1
Metadata
- Authors
- Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Pinsker, J. E., Wadwa, R. P., Dassau, E., Doyle, F. J., Anderson, S. M., Church, M. M., Dadlani, V., Ekhlaspour, L., Forlenza, G. P., Isganaitis, E., Lam, D. W., Kollman, C., & Beck, R. W.
- Affiliations
- Sansum Diabetes Research Institute (US)
- Mayo Clinic (US)
- Joslin Diabetes Center (US)
- Harvard University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-10-31
- Volume
- 381
- Issue
- 18
- Pages
- 1707-1717
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7076915
- OpenAlex
- W2981310284
- Semantic Scholar
- a8aee7f3c717498afd65ea39bd87dd1c1ea5d693
- Cited by
- 1,030
- References
- 17
- Citations by year
- 2026: 128 · 2025: 134 · 2024: 140 · 2023: 180 · 2022: 158 · 2021: 156 · 2020: 125 · 2019: 8
- FWCI
- 90.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (UC4 DK108483)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- type 1 diabetes, artificial pancreas, sensor-augmented pump, continuous glucose monitoring, glycemic control, HbA1c, hypoglycemia, hyperglycemia, insulin pump therapy, glycemic variability, HbA1c reduction, hypoglycemia risk reduction, HbA1c thresholds, hypoglycemia risk
- MeSH terms
- Adolescent, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 1, Equipment Design, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Insulin Infusion Systems, Male, Middle Aged, Pancreas, Artificial, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
